Catalio Capital Management, LP 13F holdings
Catalio Capital Management, LP reported 39 positions with a total reported value of $532.1M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: AVLN AVALYN PHARMACEUTICALS INC (10.4%), JNJ JOHNSON & JOHNSON (6.6%), GILD GILEAD SCIENCES INC (6.4%), BBIO BRIDGEBIO PHARMA INC (6.4%), SNDX SYNDAX PHARMACEUTICALS INC (5.0%). Against 2026-03-31 it opened 10 new positions and exited 12. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Catalio Capital Management, LP files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 39 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| AVLN AVALYN PHARMACEUTICALS INC | 1,675,830 | $55.2M | 10.4% |
| JNJ JOHNSON & JOHNSON | 138,946 | $35.3M | 6.6% |
| GILD GILEAD SCIENCES INC | 269,309 | $34.0M | 6.4% |
| BBIO BRIDGEBIO PHARMA INC | 455,041 | $33.9M | 6.4% |
| SNDX SYNDAX PHARMACEUTICALS INC | 1,215,698 | $26.6M | 5.0% |
| DFTX DEFINIUM THERAPEUTICS INC | 562,672 | $26.5M | 5.0% |
| BMY BRISTOL-MYERS SQUIBB CO | 412,961 | $23.8M | 4.5% |
| PBLS PARABILIS MEDICINES INC | 824,043 | $22.6M | 4.2% |
| NTRA NATERA INC | 82,181 | $22.3M | 4.2% |
| INCY INCYTE CORP | 191,627 | $21.7M | 4.1% |
| SEPN SEPTERNA INC | 536,152 | $18.0M | 3.4% |
| MLYS MINERALYS THERAPEUTICS INC | 648,722 | $17.5M | 3.3% |
| HTFL HEARTFLOW INC | 583,055 | $17.1M | 3.2% |
| CRVS CORVUS PHARMACEUTICALS INC | 1,080,888 | $16.1M | 3.0% |
| GPCR STRUCTURE THERAPEUTICS INC | 276,550 | $14.8M | 2.8% |
| PTGX PROTAGONIST THERAPEUTICS INC | 106,799 | $13.1M | 2.5% |
| IRON DISC MEDICINE INC | 159,384 | $11.7M | 2.2% |
| EW EDWARDS LIFESCIENCES CORP | 124,778 | $11.3M | 2.1% |
| AXSM AXSOME THERAPEUTICS INC. | 43,182 | $10.6M | 2.0% |
| RARE ULTRAGENYX PHARMACEUTICAL IN | 316,252 | $10.6M | 2.0% |
| KLRA KAILERA THERAPEUTICS INC | 468,750 | $10.3M | 1.9% |
| KPTI KARYOPHARM THERAPEUTICS INC | 940,855 | $9.2M | 1.7% |
| ODTX ODYSSEY THERAPEUTICS INC | 457,839 | $8.6M | 1.6% |
| ASND ASCENDIS PHARMA A/S | 31,759 | $8.5M | 1.6% |
| KARD KARDIGAN INC | 312,500 | $7.5M | 1.4% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 10 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| AVLN AVALYN PHARMACEUTICALS INC | 1,675,830 | $55.2M | 10.4% |
| JNJ JOHNSON & JOHNSON | 138,946 | $35.3M | 6.6% |
| PBLS PARABILIS MEDICINES INC | 824,043 | $22.6M | 4.2% |
| PTGX PROTAGONIST THERAPEUTICS INC | 106,799 | $13.1M | 2.5% |
| AXSM AXSOME THERAPEUTICS INC. | 43,182 | $10.6M | 2.0% |
| KLRA KAILERA THERAPEUTICS INC | 468,750 | $10.3M | 1.9% |
| ODTX ODYSSEY THERAPEUTICS INC | 457,839 | $8.6M | 1.6% |
| KARD KARDIGAN INC | 312,500 | $7.5M | 1.4% |
| FDMT 4D MOLECULAR THERAPEUTICS IN | 471,254 | $6.3M | 1.2% |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 318,407 | $2.4M | 0.5% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 12 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| TERNS PHARMACEUTICALS INC | 409,031 | $21.6M | 4.5% |
| SOLENO THERAPEUTICS INC | 577,808 | $19.3M | 4.0% |
| BSX BOSTON SCIENTIFIC CORP | 299,318 | $18.8M | 3.9% |
| CYTK CYTOKINETICS INC | 215,501 | $14.2M | 3.0% |
| ADPT ADAPTIVE BIOTECHNOLOGIES COR | 722,784 | $10.0M | 2.1% |
| KALVISTA PHARMACEUTICALS INC | 426,551 | $8.6M | 1.8% |
| QURE UNIQURE NV | 491,116 | $8.0M | 1.7% |
| ABVX ABIVAX SA | 47,193 | $5.3M | 1.1% |
| SUPN SUPERNUS PHARMACEUTICALS | 62,019 | $3.2M | 0.7% |
| PHAT PHATHOM PHARMACEUTICALS INC | 247,767 | $2.8M | 0.6% |
| NAMS NEWAMSTERDAM PHARMA COMPANY | 83,554 | $2.7M | 0.6% |
| TYRA TYRA BIOSCIENCES INC | 67,285 | $2.6M | 0.5% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| GILD GILEAD SCIENCES INC | 163,905 | 269,309 | +64.3% | $34.0M |
| SEPN SEPTERNA INC | 294,360 | 536,152 | +82.1% | $18.0M |
| MLYS MINERALYS THERAPEUTICS INC | 439,041 | 648,722 | +47.8% | $17.5M |
| HTFL HEARTFLOW INC | 403,588 | 583,055 | +44.5% | $17.1M |
| SNDX SYNDAX PHARMACEUTICALS INC | 1,043,670 | 1,215,698 | +16.5% | $26.6M |
| NTRA NATERA INC | 70,907 | 82,181 | +15.9% | $22.3M |
| CRVS CORVUS PHARMACEUTICALS INC | 891,933 | 1,080,888 | +21.2% | $16.1M |
| IRON DISC MEDICINE INC | 122,978 | 159,384 | +29.6% | $11.7M |
| IMCR IMMUNOCORE HLDGS PLC | 84,352 | 148,045 | +75.5% | $4.7M |
| BBIO BRIDGEBIO PHARMA INC | 432,014 | 455,041 | +5.3% | $33.9M |
| GPCR STRUCTURE THERAPEUTICS INC | 255,379 | 276,550 | +8.3% | $14.8M |
| INCY INCYTE CORP | 182,101 | 191,627 | +5.2% | $21.7M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| DNTH DIANTHUS THERAPEUTICS INC | 560,308 | 32,941 | -94.1% | $3.2M |
| ASND ASCENDIS PHARMA A/S | 129,111 | 31,759 | -75.4% | $8.5M |
| DFTX DEFINIUM THERAPEUTICS INC | 1,037,984 | 562,672 | -45.8% | $26.5M |
| RARE ULTRAGENYX PHARMACEUTICAL IN | 850,797 | 316,252 | -62.8% | $10.6M |
| MANE VERADERMICS INC | 173,582 | 45,856 | -73.6% | $5.6M |
| EW EDWARDS LIFESCIENCES CORP | 144,607 | 124,778 | -13.7% | $11.3M |
| DYN DYNE THERAPEUTICS INC | 282,954 | 244,929 | -13.4% | $5.4M |
| BMY BRISTOL-MYERS SQUIBB CO | 420,727 | 412,961 | -1.8% | $23.8M |
| TARA PROTARA THERAPEUTICS INC | 580,024 | 520,148 | -10.3% | $2.0M |
CIK 1958125 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
